Search results
Author(s):
Paul A Gurbel
,
David Kandzari
Added:
3 years ago
The rare but catastrophic occurrence of stent thrombosis, in particular 'late' stent thrombosis, in association with deployment of drug-eluting stents has focused attention on the adequacy of the current dual anti-platelet regimen of aspirin and clopidogrel. Stent thrombosis is due to multiple factors. These include, specific stent features (delayed healing or polymer hypersensitivity),…
View more
Author(s):
Jean-Philippe Collet
,
Jochem Wouter van Werkum
Added:
3 years ago
Antiplatelet therapy is the standard of care for patients with acute coronary syndromes (ACS) and/or patients undergoing percutaneous coronary intervention (PCI) with stenting.1–3 Plaque rupture and/or iatrogenic vascular damage during PCI would normally result in the development of intravascular thrombus. Findings across multiple investigations consistently demonstrate the effectiveness of dual…
View more
Author(s):
Nikita Lomakin
,
Anna Rudakova
,
Liudmila Buryachkovskaya
,
et al
Added:
3 years ago
Antiplatelet agents are part of secondary prevention following acute coronary syndrome (ACS). Current European and Russian guidelines recommend dual antiplatelet therapy for 1 year after ACS.1,2
Prasugrel is not marketed in Russia, so high-risk patients have been given ticagrelor. The proportion of generic clopidogrel administered has been steadily rising, with the average cost of treatment…
View more
Platelet Function Testing in Clinical Practice - Experience and Views from Europe and the US
Author(s):
Thomas O Bergmeijer
,
Jochem Wouter van Werkum
,
Udaya S Tantry
,
et al
Added:
3 years ago
Article
Author(s):
Lucas C Godoy
,
Michael E Farkouh
Added:
3 years ago
Clopidogrel is the most widely prescribed P2Y12 inhibitor in the world despite the development of newer and more potent agents.1,2 Clopidogrel is administered as a pro-drug and needs to be metabolised by the cytochrome P450 enzymes (particularly by CYP2C19) in order to have biological activity.3
Patients with loss of function (LOF) variants of the CYP2C19 gene have decreased serum levels of…
View more
Author(s):
Alberto Balbarini
,
Rossella Di Stefano
Added:
3 years ago
Since endothelial damage and dysfunction play a critical role in atherosclerotic disease, research interest has aimed at evaluating the role of endothelial progenitor cells (EPCs) in vascular endothelial layer maintenance. In contrast to local resident endothelial cells, which have a poor proliferative rate, the regenerative capacity of EPCs and their ability to integrate into blood vessels have…
View more
Author(s):
Laurent Bonello
Added:
3 years ago
Clopidogrel is a key antiplatelet agent that inhibits the second step of platelet aggregation through blockade of the P2Y12-adenosine diphosphate (ADP) receptor.1 Its use has enabled percutaneous coronary intervention (PCI) to expand by dramatically reducing thrombotic complications in acute coronary syndromes (ACSs).2,3 Since the first report by Jaremo et al. of a large inter-individual…
View more
Author(s):
Cheng Keat Tan
,
David Bin-Chia Wu
,
Seh Yi Joseph Tan
,
et al
Added:
4 months ago
Author(s):
Sasha Koul
,
David Erlinge
Added:
3 years ago
Acute coronary syndromes (ACS) are a major reason for death and morbidity in the industrialised world. One of the most successful treatments for ACS has been strategies to target the platelets and inhibit their function.
Mechanisms of Platelet Activation
Thrombus formation in the arteries is dependent on platelets and their ability to attach to the injured wall despite the rapid arterial blood…
View more
Author(s):
Gordon Lowe
,
John Yarnell
Added:
3 years ago
Clinicians and pathologists have long recognised the role of the haemostatic system in acute coronary and cerebral thrombosis, and anti-platelet, anticoagulant and fibrinolytic therapies are well established in clinical practice. Pathologists have suggested for several decades that 'hypercoagulability' contributes to the development of atheroma,1 plaque formation and rupture.2,3 Pioneering…
View more